Clinical trials: Locally Advanced Nasopharyngeal Carcinoma, active
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction…
- Trial name
- NCT07328841
- Testing
- Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy
- Where
- 12 sites in China
- Volunteers
- 456 people
- Sponsor
- Ming-Yuan Chen
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Nasopharyngeal Cancinoma (NPC)
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
Based on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified.
- Trial name
- NCT07496190
- Testing
- Becotatug vedotin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Nasopharyngeal Carcinoma
GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma
The goal of this clinical trial is to learn if the regimen of gemcitabine, cisplatin combined with nimotuzumab and sintilimab works to treat locally advanced nasopharyngeal carcinoma before chemoradiotherapy.
- Trial name
- NCT06490341
- Testing
- GP Regimen, Nimotuzumab, Sintilimab
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharangeal Cancer
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
In this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to…
- Trial name
- NCT07392320
- Testing
- TP+PD1+CCRT, PD-1 Monoclonal Antibody, Capecitabine
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Nasopharyngeal Carcinoma
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced…
- Trial name
- NCT07177443
- Testing
- Radiotherapy, Serplulimab, Cisplatin
- Where
- China
- Volunteers
- 710 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
This is a prospective, open-label, multicenter, single-arm clinical study. A total of 30 patients with locally advanced nasopharyngeal carcinoma who have not received prior systemic treatment are planned to be enrolled at three…
- Conditions
- Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
- Trial name
- NCT07085234
- Testing
- Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Locally Advanced Nasopharyngeal Carcinoma
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy combined with concurrent chemoradiotherapy in patients…
- Trial name
- NCT05062005
- Testing
- Induction Chemotherapy, Concurrent Chemotherapy, Definitive Radiotherapy
- Where
- China
- Volunteers
- 447 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma…
- Conditions
- Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
- Trial name
- NCT06475300
- Testing
- BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
TPF, Immunotherapy
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NPC is one of the most common malignant tumors in the head and neck region of China. Currently, the main treatment regimen for LA-NPC is radical concurrent chemoradiotherapy combined with induction or adjuvant chemotherapy.
- Conditions
- TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
- Trial name
- NCT06781112
- Testing
- albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Weiwei Zhang
Nasopharyngeal Carcinoma, Pathologic Complete Response
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle…
- Conditions
- Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
- Trial name
- NCT06182657
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Nasopharyngeal Carcinoma (NPC)
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the…
- Trial name
- NCT07136519
- Testing
- Toripalimab, Omega-3, radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II…
- Trial name
- NCT06851247
- Testing
- Toripalimab, Anlotinib, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT06055816
- Testing
- Endostar and Envafolimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital